- The FDA has approved one month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication for high bleeding risk patients implanted with Medtronic's (NYSE:MDT) Resolute Onyx drug-eluting stent (DES), the only such device with this indication in the U.S.
- Resolute Onyx DES was CE Mark'd in May for one-month DAPT in high bleeding risk patients.
- https://seekingalpha.com/news/3618791-medtronic-nabs-expanded-u-s-label-for-resolute-onyx-stent
Thursday, October 1, 2020
Medtronic nabs expanded U.S. label for Resolute Onyx stent
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.